- Home
- NAMS
NAMS
NewAmsterdam Pharma Company N.V.
as 04-18-2025 1:40pm EST
| Founded: | 2019 | Country: | Netherlands |
| Employees: | N/A | City: | NARRDEN |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $43.17 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.06 - $27.29 | Next Earning Date: | 05-05-2025 |
| Revenue: | $45,563,000 | Revenue Growth: | 223.37% |
| Revenue Growth (this year): | -59.66% | Revenue Growth (next year): | -7.33% |
Latest NewAmsterdam Pharma Company N.V. News
NAMS Breaking Stock News: Dive into NAMS Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
GlobeNewswire
15 days ago
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investor's Business Daily
19 days ago
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
GlobeNewswire
19 days ago
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
Simply Wall St.
2 months ago
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year
Simply Wall St.
2 months ago
NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
2 months ago
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
2 months ago
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
Compare NAMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAMS NewAmsterdam Pharma Company N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.